Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACCELERON PHARMA INC.

(XLRN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
172.51(c) 173.75(c) 173.95(c) 173.78(c) 173.73 Last
499 975 633 929 196 871 335 704 85 316 Volume
-0.71% +0.72% +0.12% -0.10% -0.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 134 M - -
Net income 2021 -241 M - -
Net cash position 2021 482 M - -
P/E ratio 2021 -43,3x
Yield 2021 -
Sales 2022 201 M - -
Net income 2022 -203 M - -
Net cash position 2022 297 M - -
P/E ratio 2022 -50,3x
Yield 2022 -
Capitalization 10 626 M 10 626 M -
EV / Sales 2021 75,5x
EV / Sales 2022 51,3x
Nbr of Employees 312
Free-Float 87,6%
More Financials
Company
Acceleron Pharma Inc., incorporated on June 13, 2003, is a biopharmaceutical company. The Company is focused on its research, development, and commercialization efforts in pulmonary and hematologic diseases. Its research is focused on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta) protein superfamily. The Company's product pipeline includes... 
More about the company
Ratings of Acceleron Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ACCELERON PHARMA INC.
10/21MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
MT
10/18ACCELERON PHARMA ALERT : Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender ..
BU
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
MT
10/13SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Acceleron Pha..
PR
10/13ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
RE
10/13ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
RE
10/12MERCK : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share
MT
10/07ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target
MT
10/04ACCELERON PHARMA : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong..
MT
10/01ACCELERON INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
10/01SHAREHOLDER INVESTIGATION : Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Sharehol..
PR
10/01ACCELERON PHARMA : Oppenheimer Suspends Rating for Acceleron Pharma, $160 Price Target on ..
MT
10/01ACCELERON PHARMA : Morgan Stanley Downgrades Acceleron Pharma to Equalweight from Overweig..
MT
10/01ACCELERON PHARMA : Barclays Downgrades Acceleron Pharma to Equal-Weight Rating From Overwe..
MT
10/01WALL STREET STOCK EXCHANGE : Autumn cold snap
More news
News in other languages on ACCELERON PHARMA INC.
10/21Bristol-Myers va céder sa participation dans Acceleron avant l'acquisition de 11,5 mill..
10/14Un actionnaire d'Acceleron Pharma affirme que l'offre de Merck & Co. sous-évalue consid..
10/13Holocene Advisors estime que l'offre de Merck sous-évalue Acceleron.
10/13Holocene Advisors estime que l'offre de Merck sous-évalue Acceleron.
10/12MERCK : lancement d'une OPA sur Acceleron Pharma
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | XLRN | US00434H1086 | MarketScreener
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 173,78 $
Average target price 177,36 $
Spread / Average Target 2,06%
EPS Revisions
Managers and Directors
Habib J. Dable President, Chief Executive Officer & Director
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Francois Nader Non-Executive Chairman
Ravindra Kumar Chief Scientific Officer & Senior Vice President
Jay T. Backstrom Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ACCELERON PHARMA INC.35.83%10 626
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992